Comprehensive genomic profiling for homologous recombination deficiency guides PARP inhibitor therapy recommendations in ovarian cancer
Molecular profiling with F1CDx proved to be a technically feasible, clinically impactful, and time-efficient assay, demonstrating its value in supporting molecular-guided PARPi therapy recommendations in the routine care of HGSOC patients.
Authors
- Isabell Witzel (ORCID: https://orcid.org/0000-0002-8734-4521)
- Alp Inci (ORCID: https://orcid.org/0009-0009-7671-7570)
- Martin Zoche (ORCID: https://orcid.org/0000-0002-0421-7229)
- Holger Moch (ORCID: https://orcid.org/0000-0002-7986-2839)
- Eleftherios Pierre Samartzis (ORCID: https://orcid.org/0000-0002-8246-5842)
- Sepehr Rahmani-Khajouei
Institutions
- University of Zurich (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Pathology & Oncology Research
- Published
- 2025-11-13
- DOI
- https://doi.org/10.3389/pore.2025.1612266
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00